<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="review-article" dtd-version="2.3">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Genet.</journal-id>
<journal-title>Frontiers in Genetics</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Genet.</abbrev-journal-title>
<issn pub-type="epub">1664-8021</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fgene.2019.01138</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Genetics</subject>
<subj-group>
<subject>Mini Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Changes in Deoxyribonucleic Acid Methylation Contribute to the Pathophysiology of Multiple Sclerosis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Celarain</surname>
<given-names>Naiara</given-names>
</name>
<xref ref-type="author-notes" rid="fn001"><sup>*</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Tomas-Roig</surname>
<given-names>Jordi</given-names>
</name>
<xref ref-type="author-notes" rid="fn001"><sup>*</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/324552"/>
</contrib>
</contrib-group>
<aff id="aff1"><institution>Girona Neuroimmunology and Multiple Sclerosis Unit (UNIEM), Dr. Josep Trueta University Hospital, Girona Biomedical Research Institute (IDIBGI)</institution>, <addr-line>Girona</addr-line>, <country>Spain</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Trygve Tollefsbol, University of Alabama at Birmingham, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Richard Koche, Memorial Sloan Kettering Cancer Center, United States; Bruce V Taylor, University of Tasmania, Australia</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Naiara Celarain, <email xlink:href="mailto:ncelarain@idibgi.org">ncelarain@idibgi.org</email>; Jordi Tomas-Roig, <email xlink:href="mailto:jtomas@idibgi.org">jtomas@idibgi.org</email></p>
</fn>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Epigenomics and Epigenetics, a section of the journal Frontiers in Genetics</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>12</day>
<month>11</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>10</volume>
<elocation-id>1138</elocation-id>
<history>
<date date-type="received">
<day>03</day>
<month>06</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>21</day>
<month>10</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2019 Celarain and Tomas-Roig</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>Celarain and Tomas-Roig</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Multiple sclerosis (MS) is an autoimmune disease of the central nervous system characterized by loss of coordination, weakness, dysfunctions in bladder capacity, bowel movement, and cognitive impairment. Thus, the disease leads to a significant socioeconomic burden. In the pathophysiology of the disease, both genetic and environmental risk factors are involved. Gene x environment interaction is modulated by epigenetic mechanisms. Epigenetics refers to a sophisticated system that regulates gene expression with no changes in the DNA sequence. The most studied epigenetic mechanism is the DNA methylation. In this review, we summarize the data available from the current literature by grouping sets of differentially methylated genes in distinct biological categories: the immune system including innate and adaptive response, the DNA damage, and the central nervous system.</p>
</abstract>
<kwd-group>
<kwd>multiple sclerosis</kwd>
<kwd>deoxyribonucleic acid methylation</kwd>
<kwd>immune cells</kwd>
<kwd>central nervous system</kwd>
<kwd>deoxyribonucleic acid damage</kwd>
</kwd-group>
<contract-sponsor id="cn001">Instituto de Salud Carlos III<named-content content-type="fundref-id">10.13039/501100004587</named-content>
</contract-sponsor>
<counts>
<fig-count count="1"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="45"/>
<page-count count="7"/>
<word-count count="3541"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Multiple sclerosis (MS) is a potentially disabling central nervous system (CNS) disease characterized by inflammation, demyelination, and axonal degeneration. The pathophysiological mechanisms involved in this autoimmune disease differ between patients. In MS pathogenesis, antigen-presenting cells (APCs) stimulate CD4+ T cells in the periphery, favoring their differentiation into CD4+ T helper (Th) cells. Upon their activation, these immune cells cross the blood&#x2013;brain barrier (BBB) and migrate into the brain, where they are reactivated by resident APCs. Proinflammatory cytokines and chemokines are released by reactivated CD4+ T cells, while infiltrated cytotoxic CD8+ T cells impair neuronal integrity. In parallel, plasma B cells release antibodies against self myelin epitopes, contributing to demyelination (<xref ref-type="bibr" rid="B9">Ghasemi et al., 2017</xref>) (<xref ref-type="supplementary-material" rid="SM1"><bold>Figure S1</bold></xref>).</p>
<p>An individual&#x2019;s genetic background and exposure to environmental factors confer risk of developing MS through epigenetic modifications (<xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref>). DNA methylation (DNAme) is the most common epigenetic mechanism in somatic cells. This process occurs mainly in regulatory and promoter regions, where cytosine-guanine dinucleotides are markedly present (<xref ref-type="bibr" rid="B43">Weber et al., 2007</xref>). Although the precise mechanism of action of DNAme in MS remains to be fully elucidated, several studies have reported differentially methylated regions in either lymphocytes or peripheral blood mononuclear cells (PBMCs) and in <italic>post-mortem</italic> brain tissue (<xref ref-type="supplementary-material" rid="SM1"><bold>Table S1</bold></xref>).</p>
<fig id="f1" position="float">
<label>Figure 1</label>
<caption>
<p>Epigenetic modifications. These mechanisms are crucial for regulating gene transcription and chromatin architecture. Among them, we can highlight histone modifications, DNA methylation, and microRNAs. Covalent modifications of histones include acetylation, phosphorylation, sumoylation, ubiquitination, and methylation. DNA methylation is the most common epigenetic mechanism that occurs mainly in enriched CG dinucleotides regions in somatic cells. miRNAs are small non-coding RNA molecules that participate in RNA silencing. DNAme, DNA methylation; miRNA, microRNA; Me, methylation; Ub, ubiquitination; Ac, acetylation; P, phosphorylation.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fgene-10-01138-g001.tif"/>
</fig>
<p>In this study, sets of differentially methylated genes described in the relevant literature are compared using Venn diagrams in order to determine the common, overlapping genes (<xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>). Although the studies included in this review have used a variety of methods, target samples, and subjects at different stages of the disease with distinct demographic characteristics that may contribute to DNAme heterogeneity, we assume that the common results reported at cell type level by different case studies could potentially explain in part MS pathophysiology. These results are summarized below.</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>Overlapped genes obtained after Venn diagram analysis.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top">Gene symbol</th>
<th valign="top">Reference</th>
<th valign="top">Methylation status</th>
<th valign="top">Comparison</th>
<th valign="top">Target sample</th>
<th valign="top">Biological function</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top"><bold>AHRR</bold></td>
<td valign="top"><xref ref-type="bibr" rid="B5">Chomyk et al., 2017</xref></td>
<td valign="top">Hypo</td>
<td valign="top">Within MS patients</td>
<td valign="top">NAWM; demyelinated hippocampus</td>
<td valign="top">Homeostasis of the immune system</td>
</tr>
<tr>
<td valign="top"/>
<td valign="top"><xref ref-type="bibr" rid="B12">Graves et al., 2014</xref></td>
<td valign="top">Hypo</td>
<td valign="top">RRMS <italic>vs.</italic> CTR</td>
<td valign="top">CD4+ T cells</td>
<td valign="top"/>
</tr>
<tr>
<td valign="top"/>
<td valign="top"><xref ref-type="bibr" rid="B28">Marabita et al., 2017</xref></td>
<td valign="top">Hypo</td>
<td valign="top">Smoker MS <italic>vs.</italic> non-smoker MS</td>
<td valign="top">PMBCs</td>
<td valign="top"/>
</tr>
<tr>
<td valign="top"><bold>RASA3</bold></td>
<td valign="top"><xref ref-type="bibr" rid="B5">Chomyk et al., 2017</xref></td>
<td valign="top">Hypo</td>
<td valign="top">Within MS patients</td>
<td valign="top">NAWM; demyelinated hippocampus</td>
<td valign="top">Inhibition of pathogenic Th17 cells</td>
</tr>
<tr>
<td valign="top"/>
<td valign="top"><xref ref-type="bibr" rid="B17">Huynh et al., 2014</xref></td>
<td valign="top">Hyper</td>
<td valign="top">MS <italic>vs.</italic> CTR</td>
<td valign="top">NAWM</td>
<td valign="top"/>
</tr>
<tr>
<td valign="top"/>
<td valign="top"><xref ref-type="bibr" rid="B21">Kulakova et al., 2016</xref></td>
<td valign="top">Hyper</td>
<td valign="top">RRMS <italic>vs.</italic> SPMS</td>
<td valign="top">PMBCs</td>
<td valign="top"/>
</tr>
<tr>
<td valign="top"><bold>MORN1</bold></td>
<td valign="top"><xref ref-type="bibr" rid="B12">Graves et al., 2014</xref></td>
<td valign="top">Hyper</td>
<td valign="top">RRMS <italic>vs.</italic> CTR</td>
<td valign="top">CD4+ T cells</td>
<td valign="top">Regulation of calcium homeostasis</td>
</tr>
<tr>
<td valign="top"/>
<td valign="top"><xref ref-type="bibr" rid="B27">Maltby et al., 2015</xref></td>
<td valign="top">Hyper</td>
<td valign="top">MS <italic>vs.</italic> CTR</td>
<td valign="top">CD8+ T cells</td>
<td valign="top"/>
</tr>
<tr>
<td valign="top"><bold>KIF25</bold></td>
<td valign="top"><xref ref-type="bibr" rid="B5">Chomyk et al., 2017</xref></td>
<td valign="top">Hypo</td>
<td valign="top">Within MS patients</td>
<td valign="top">NAWM; demyelinated hippocampus</td>
<td valign="top">Motor protein involved in trafficking of vesicles, organelles, and proteins through the cytoskeleton</td>
</tr>
<tr>
<td valign="top"/>
<td valign="top"><xref ref-type="bibr" rid="B12">Graves et al., 2014</xref></td>
<td valign="top">Hypo</td>
<td valign="top">RRMS <italic>vs.</italic> CTR</td>
<td valign="top">CD4+ T cells</td>
<td valign="top"/>
</tr>
<tr>
<td valign="top"><bold>TGFBI</bold></td>
<td valign="top"><xref ref-type="bibr" rid="B5">Chomyk et al., 2017</xref></td>
<td valign="top">Hypo</td>
<td valign="top">Within MS patients</td>
<td valign="top">NAWM; demyelinated hippocampus</td>
<td valign="top">Participate in calcium signaling and inflammation process</td>
</tr>
<tr>
<td valign="top"/>
<td valign="top"><xref ref-type="bibr" rid="B12">Graves et al., 2014</xref></td>
<td valign="top">Hyper</td>
<td valign="top">RRMS <italic>vs.</italic> CTR</td>
<td valign="top">CD4+ T cells</td>
<td valign="top"/>
</tr>
<tr>
<td valign="top"><bold>USP35</bold></td>
<td valign="top"><xref ref-type="bibr" rid="B12">Graves et al., 2014</xref></td>
<td valign="top">Hypo</td>
<td valign="top">RRMS <italic>vs.</italic> CTR</td>
<td valign="top">CD4+ T cells</td>
<td valign="top">Deubiquitinating enzyme involved in type I interferon signaling</td>
</tr>
<tr>
<td valign="top"/>
<td valign="top"><xref ref-type="bibr" rid="B21">Kulakova et al., 2016</xref></td>
<td valign="top">Hyper</td>
<td valign="top">RRMS <italic>vs.</italic> SPMS</td>
<td valign="top">PMBCs</td>
<td valign="top"/>
</tr>
<tr>
<td valign="top"><bold>MICB</bold></td>
<td valign="top"><xref ref-type="bibr" rid="B12">Graves et al., 2014</xref></td>
<td valign="top">Hypo</td>
<td valign="top">RRMS <italic>vs.</italic> CTR</td>
<td valign="top">CD4+ T cells</td>
<td valign="top">Involved in innate immune system regulation</td>
</tr>
<tr>
<td valign="top"/>
<td valign="top"><xref ref-type="bibr" rid="B17">Huynh et al., 2014</xref></td>
<td valign="top">Hypo</td>
<td valign="top">MS <italic>vs.</italic> CTR</td>
<td valign="top">NAWM</td>
<td valign="top"/>
</tr>
<tr>
<td valign="top"><bold>IGSF9B</bold></td>
<td valign="top"><xref ref-type="bibr" rid="B5">Chomyk et al., 2017</xref></td>
<td valign="top">Hyper</td>
<td valign="top">Within MS patients</td>
<td valign="top">NAWM; demyelinated hippocampus</td>
<td valign="top">Cell adhesion molecule involved in GABAergic circuits</td>
</tr>
<tr>
<td valign="top"/>
<td valign="top"><xref ref-type="bibr" rid="B21">Kulakova et al., 2016</xref></td>
<td valign="top">Hyper</td>
<td valign="top">PPMS <italic>vs.</italic> CTR</td>
<td valign="top">PMBCs</td>
<td valign="top"/>
</tr>
<tr>
<td valign="top"><bold>PSD3</bold></td>
<td valign="top"><xref ref-type="bibr" rid="B4">Bos et al., 2015</xref></td>
<td valign="top">Hypo</td>
<td valign="top">RRMS <italic>vs.</italic> CTR</td>
<td valign="top">CD8+ T cells</td>
<td valign="top">Control of neurite formation, spine density, trafficking of synaptic vesicles</td>
</tr>
<tr>
<td valign="top"/>
<td valign="top"><xref ref-type="bibr" rid="B5">Chomyk et al., 2017</xref></td>
<td valign="top">Hypo</td>
<td valign="top">Within MS patients</td>
<td valign="top">NAWM; demyelinated hippocampus</td>
<td valign="top"/>
</tr>
<tr>
<td valign="top"><bold>HLA-F</bold></td>
<td valign="top"><xref ref-type="bibr" rid="B17">Huynh et al., 2014</xref></td>
<td valign="top">Hypo</td>
<td valign="top">MS <italic>vs.</italic> CTR</td>
<td valign="top">NAWM</td>
<td valign="top">Regulation of immune response through antigen-processing mechanism</td>
</tr>
<tr>
<td valign="top"/>
<td valign="top"><xref ref-type="bibr" rid="B21">Kulakova et al., 2016</xref></td>
<td valign="top">Hypo</td>
<td valign="top">PPMS <italic>vs.</italic> CTR</td>
<td valign="top">PMBCs</td>
<td valign="top"/>
</tr>
<tr>
<td valign="top"><bold>GNAS</bold></td>
<td valign="top"><xref ref-type="bibr" rid="B17">Huynh et al., 2014</xref></td>
<td valign="top">Hypo</td>
<td valign="top">MS <italic>vs.</italic> CTR</td>
<td valign="top">NAWM</td>
<td valign="top">Involved in Th17 activation and autoimmunity</td>
</tr>
<tr>
<td valign="top"/>
<td valign="top"><xref ref-type="bibr" rid="B21">Kulakova et al., 2016</xref></td>
<td valign="top">Hypo</td>
<td valign="top">RRMS <italic>vs.</italic> CTR</td>
<td valign="top">PMBCs</td>
<td valign="top"/>
</tr>
<tr>
<td valign="top"><bold>ATP11A</bold></td>
<td valign="top"><xref ref-type="bibr" rid="B17">Huynh et al., 2014</xref></td>
<td valign="top">Hyper</td>
<td valign="top">MS <italic>vs.</italic> CTR</td>
<td valign="top">NAWM</td>
<td valign="top">Possess an anti-inflammatory activity through internalization of macrophage TLR-4</td>
</tr>
<tr>
<td valign="top"/>
<td valign="top"><xref ref-type="bibr" rid="B21">Kulakova et al., 2016</xref></td>
<td valign="top">Hypo</td>
<td valign="top">RRMS <italic>vs.</italic> CTR</td>
<td valign="top">PMBCs</td>
<td valign="top"/>
</tr>
<tr>
<td valign="top"><bold>HOXC4</bold></td>
<td valign="top"><xref ref-type="bibr" rid="B17">Huynh et al., 2014</xref></td>
<td valign="top">Hypo</td>
<td valign="top">MS <italic>vs.</italic> CTR</td>
<td valign="top">NAWM</td>
<td valign="top">Involved in vasculature pathways, nucleosome organization, and autoimmune disorders</td>
</tr>
<tr>
<td valign="top"/>
<td valign="top"><xref ref-type="bibr" rid="B21">Kulakova et al., 2016</xref></td>
<td valign="top">Hypo</td>
<td valign="top">RRMS <italic>vs.</italic> CTR</td>
<td valign="top">PMBCs</td>
<td valign="top"/>
</tr>
<tr>
<td valign="top"><bold>RARA</bold></td>
<td valign="top"><xref ref-type="bibr" rid="B17">Huynh et al., 2014</xref></td>
<td valign="top">Hypo</td>
<td valign="top">MS <italic>vs.</italic> CTR</td>
<td valign="top">NAWM</td>
<td valign="top">Regulation of development, differentiation, apoptosis, granulopoiesis, and transcription of clock genes</td>
</tr>
<tr>
<td valign="top"/>
<td valign="top"><xref ref-type="bibr" rid="B28">Marabita et al., 2017</xref></td>
<td valign="top">Hypo</td>
<td valign="top">Smoker MS <italic>vs.</italic> non-smoker MS</td>
<td valign="top">PMBCs</td>
<td valign="top"/>
</tr>
<tr>
<td valign="top"><bold>PTPRN2</bold></td>
<td valign="top"><xref ref-type="bibr" rid="B4">Bos et al., 2015</xref></td>
<td valign="top">Hypo</td>
<td valign="top">RRMS <italic>vs.</italic> CTR</td>
<td valign="top">CD8+ T cells</td>
<td valign="top">Proliferation of regulatory T cells</td>
</tr>
<tr>
<td valign="top"/>
<td valign="top"><xref ref-type="bibr" rid="B17">Huynh et al., 2014</xref></td>
<td valign="top">Hyper</td>
<td valign="top">MS <italic>vs.</italic> CTR</td>
<td valign="top">NAWM</td>
<td valign="top"/>
</tr>
<tr>
<td valign="top"><bold>CDH1</bold></td>
<td valign="top"><xref ref-type="bibr" rid="B17">Huynh et al., 2014</xref></td>
<td valign="top">Hyper</td>
<td valign="top">MS <italic>vs.</italic> CTR</td>
<td valign="top">NAWM</td>
<td valign="top">Cell adhesion protein involved in synaptogenesis</td>
</tr>
<tr>
<td valign="top"/>
<td valign="top"><xref ref-type="bibr" rid="B24">Liggett et al., 2010</xref></td>
<td valign="top">Hyper</td>
<td valign="top">RRMS (r) <italic>vs.</italic> CTR<break/>RRMS (r) <italic>vs.</italic> RRMS (e)</td>
<td valign="top">cfpDNA</td>
<td valign="top"/>
</tr>
<tr>
<td valign="top"><bold>LINE-1</bold></td>
<td valign="top"><xref ref-type="bibr" rid="B6">Dunaeva et al., 2018</xref></td>
<td valign="top">Hyper</td>
<td valign="top">RRMS <italic>vs.</italic> CTR</td>
<td valign="top">cfDNA (serum)</td>
<td valign="top">Retrotransposons</td>
</tr>
<tr>
<td valign="top"/>
<td valign="top"><xref ref-type="bibr" rid="B35">Pinto-Medel et al., 2017</xref></td>
<td valign="top">Hyper</td>
<td valign="top">MS na&#xef;ve <italic>vs.</italic> MS IFN-&#x3b2; 1 year <italic>vs.</italic> CTR</td>
<td valign="top">PMBCs</td>
<td valign="top"/>
</tr>
<tr>
<td valign="top"><bold>RUNX3</bold></td>
<td valign="top"><xref ref-type="bibr" rid="B17">Huynh et al., 2014</xref></td>
<td valign="top">Hypo</td>
<td valign="top">MS <italic>vs.</italic> CTR</td>
<td valign="top">NAWM</td>
<td valign="top">Coordination of DC, T, and NK cell differentiation</td>
</tr>
<tr>
<td valign="top"/>
<td valign="top"><xref ref-type="bibr" rid="B37">Sokratous et al., 2018</xref></td>
<td valign="top">Hyper</td>
<td valign="top">RRMS (e), RRMS (r) <italic>vs.</italic> CTR</td>
<td valign="top">Whole blood</td>
<td valign="top"/>
</tr>
<tr>
<td valign="top"><bold>CDKN2A</bold></td>
<td valign="top"><xref ref-type="bibr" rid="B24">Liggett et al., 2010</xref></td>
<td valign="top">Hyper</td>
<td valign="top">RRMS (r) <italic>vs.</italic> CTR</td>
<td valign="top">cfpDNA</td>
<td valign="top">Regulation of cell cycle</td>
</tr>
<tr>
<td valign="top"/>
<td valign="top"><xref ref-type="bibr" rid="B37">Sokratous et al., 2018</xref></td>
<td valign="top">Hyper</td>
<td valign="top">RRMS (e), RRMS (r)<break/><italic>vs.</italic> CTR</td>
<td valign="top">Whole blood</td>
<td valign="top"/>
</tr>
<tr>
<td valign="top"><bold>SOCS1</bold></td>
<td valign="top"><xref ref-type="bibr" rid="B24">Liggett et al., 2010</xref></td>
<td valign="top">Hyper</td>
<td valign="top">RRMS (r) <italic>vs.</italic> CTR</td>
<td valign="top">cfpDNA</td>
<td valign="top">Regulation of proinflammatory cytokines release</td>
</tr>
<tr>
<td valign="top"/>
<td valign="top"><xref ref-type="bibr" rid="B37">Sokratous et al., 2018</xref></td>
<td valign="top">Hyper</td>
<td valign="top">RRMS (e) RRMS (r)<break/><italic>vs.</italic> CTR</td>
<td valign="top">Whole blood</td>
<td valign="top"/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>NAWM, normal appearing white matter; PBMCs, peripheral blood mononuclear cells; cfpDNA, cell-free plasma DNA; cfDNA, circulating free DNA.</p>
</table-wrap-foot>
</table-wrap>
<sec id="s1_1">
<title>The Immune System</title>
<p>The homeostasis of the immune system is modulated by the aryl hydrocarbon receptor (AHR). AHR activity is negatively regulated by the encoded protein for the aryl hydrocarbon receptor repressor (AHRR). MS patients showed lower expression levels of circulating AHR than their matched controls (<xref ref-type="bibr" rid="B31">Neavin et al., 2018</xref>). In line with these findings, lower DNAme levels for AHRR have been measured in demyelinated hippocampi (<xref ref-type="bibr" rid="B5">Chomyk et al., 2017</xref>), CD4+ T cells (<xref ref-type="bibr" rid="B12">Graves et al., 2014</xref>), and PBMCs (<xref ref-type="bibr" rid="B28">Marabita et al., 2017</xref>) of MS patients. This suggests that immune differentiation as well as the clinical course are compromised in MS (<xref ref-type="bibr" rid="B31">Neavin et al., 2018</xref>). Furthermore, it is widely accepted that the major histocompatibility complex (MHC) plays a key role in the genetic susceptibility to MS. Two polymorphic genes, termed MHC class I chain-related gene A (MICA) and MHC class I chain-related gene B (MICB), are located within the MHC class I region. These molecules interact with specific receptors constitutively expressed in natural killer (NK) and T cells. The expression of MICB proteins in circulating PBMCs stimulates autoreactive T cells and favors MS progression (<xref ref-type="bibr" rid="B1">Abediankenari et al., 2011</xref>). Similarly, <xref ref-type="bibr" rid="B7">Fernandez-Morera et al. (2008)</xref> found that the MICB*004 allele was significantly higher in MS patients than their matched controls. MS patients displayed lower DNAme levels for MICB compared to controls (<xref ref-type="bibr" rid="B12">Graves et al., 2014</xref>; <xref ref-type="bibr" rid="B17">Huynh et al., 2014</xref>), in agreement with <xref ref-type="bibr" rid="B1">Abediankenari et al. (2011)</xref> and <xref ref-type="bibr" rid="B7">Fernandez-Morera et al. (2008)</xref>. Runt-related transcription factor 3 (RUNX3) is expressed in dendritic cells (DCs), as well as T and NK cells, regulating their differentiation. In contrast, cyclin-dependent kinase inhibitor 2A (CDKN2A) controls the cell cycle, and it is abundantly expressed in oligodendrocytes and CD4+ and CD8+ T cells. In PBMCs collected from MS patients, both genes were underexpressed, which indicates a misbalance in CD4/CD8 T cell differentiation (<xref ref-type="bibr" rid="B34">Parnell et al., 2014</xref>). In line with these findings, elevated levels of DNAme for RUNX3 and CDKN2A were found in MS patients compared to controls (<xref ref-type="bibr" rid="B24">Liggett et al., 2010</xref>; <xref ref-type="bibr" rid="B37">Sokratous et al., 2018</xref>).</p>
</sec>
<sec id="s1_2">
<title>Innate Immune Response</title>
<p>In DCs, high levels of cyclic adenosine monophosphate (cAMP) activate Th17 response through the stimulation of guanine nucleotide-binding protein, alpha stimulating (GNAS). High levels of activated Th17 cells are associated with autoimmunity (<xref ref-type="bibr" rid="B22">Lee et al., 2015</xref>). In line with these findings, other studies have revealed a lower number of DNAme groups to GNAS (<xref ref-type="bibr" rid="B17">Huynh et al., 2014</xref>; <xref ref-type="bibr" rid="B21">Kulakova et al., 2016</xref>) and consequently, an overactivation of Th17 cells. It is well-known that the recognition of CNS self-epitopes by monocytes facilitates type I interferon (IFN) release and thus, autoimmunity. IFN signaling is regulated by ubiquitination mechanisms. Ubiquitin-specific peptidase 35 (USP35), a member of the deubiquitinating enzyme family, reverses the process of ubiquitination and confers neuroprotection. During an inflammatory response, USP35 is underexpressed in monocytes. The expression of this deubiquitinating enzyme is higher when the inflammation is mitigated (<xref ref-type="bibr" rid="B25">Liu et al., 2018</xref>). Thus, we can speculate that a high number of DNAme groups to USP35 might occur in parallel with a relapsing MS course (<xref ref-type="bibr" rid="B21">Kulakova et al., 2016</xref>), while a hypomethylated pattern could favor a remitting course for the disease (<xref ref-type="bibr" rid="B12">Graves et al., 2014</xref>). In macrophages, the group of phosphatidylserines, a canonical substrate for ATPase phospholipid transporting 11A (ATP11A), is charged negatively and participates in the internalization of toll-like receptor 4 (TLR4). The internalization of TLR4 is essential to restricting long-term inflammatory responses. Deletion of ATP11A in humans causes an exacerbated inflammatory response (<xref ref-type="bibr" rid="B42">van der Mark et al., 2017</xref>). The addition of DNAme groups to ATP11A, which <xref ref-type="bibr" rid="B17">Huynh et al. (2014)</xref> described in the CNS of MS patients, might result in lower protein content and, consequently, chronic inflammation. However, <xref ref-type="bibr" rid="B21">Kulakova et al. (2016)</xref> found an opposite effect, indicating that the expression of ATP11A was presumably higher in MS patients than controls. This discrepancy might suggest that the study of DNAme derived from PBMCs (<xref ref-type="bibr" rid="B21">Kulakova et al., 2016</xref>) was conducted during the remitting course of MS, when no signs of inflammation were present.</p>
</sec>
<sec id="s1_3">
<title>Adaptive Immune Response</title>
<p>CD4+ T cells proliferate into effector T cells in order to provide the most effective response to maintain immune homeostasis. Among CD4+ T cells, the Th17 subset regulates the immune response against autoimmunity. The generation of pathogenic Th17 (pTh17) cells is associated with an upregulation of RAS p21 protein activator 3 (RASA3). In contrast, reduced expression of RASA3 suppresses pTh17 cell generation <italic>via</italic> enhanced interleukin 4 synthesis (<xref ref-type="bibr" rid="B45">Wu et al., 2018</xref>). An elevated number of methyl groups for RASA3 was measured in normal-appearing white matter (NAWM) (<xref ref-type="bibr" rid="B17">Huynh et al., 2014</xref>) and PBMCs (<xref ref-type="bibr" rid="B21">Kulakova et al., 2016</xref>), presumably due to the fact that MS patients displayed no radiological disease activity and absence of pTh17 cells. In contrast, <xref ref-type="bibr" rid="B5">Chomyk et al. (2017)</xref> demonstrated a hypomethylated RASA3 pattern in the hippocampus during ongoing demyelination. Therefore, the migration of pathogenic lymphocytes into the MS brain originates in the destruction of myelin sheath and axonal degeneration through elevated levels of RASA3 (<xref ref-type="bibr" rid="B45">Wu et al., 2018</xref>). The activation of homeobox C4 (HOXC4) promotes the proliferation and differentiation of B cells (<xref ref-type="bibr" rid="B33">Park et al., 2013</xref>). High mRNA transcription rates for HOXC4 are associated with dysfunctions in vasculature pathways and nucleosome organization (<xref ref-type="bibr" rid="B29">Marchetti et al., 2018</xref>) and have also been observed in autoimmune disorders (<xref ref-type="bibr" rid="B33">Park et al., 2013</xref>). A lower number of methylated groups to HOXC4 would result in elevated protein levels, contributing to autoimmunity (<xref ref-type="bibr" rid="B17">Huynh et al., 2014</xref>; <xref ref-type="bibr" rid="B21">Kulakova et al., 2016</xref>). The proliferation of regulatory T cells is achieved through the interaction of protein tyrosine phosphatase receptor type N2 (PTPRN2) with SMAD family member 3 (SMAD3) (<xref ref-type="bibr" rid="B23">Lee et al., 2016</xref>). A hypomethylated pattern of PTPRN2 has been described in T cells collected from MS patients (<xref ref-type="bibr" rid="B4">Bos et al., 2015</xref>). Thus, high levels of PTPRN2 might potentiate the proliferation of regulatory T cells. Interestingly, transforming growth factor, beta-induced (TGFBI) prevents autoimmunity by promoting T cell activation through Ca<sup>2+</sup>-calcineurin signaling (<xref ref-type="bibr" rid="B11">Graca, 2007</xref>). The addition of methyl groups to TGFBI in CD4+ T cells derived from MS patients (<xref ref-type="bibr" rid="B12">Graves et al., 2014</xref>) might prevent autoimmune reactivity favoring Ca<sup>2+</sup>-calcineurin signaling and T cell activation (<xref ref-type="bibr" rid="B11">Graca, 2007</xref>). Cytokines participate in the differentiation, maturation, and survival of immune cells. Suppressor of cytokine signaling 1 (SOCS1) regulates specifically the release of proinflammatory cytokines in MS. Under pathophysiological conditions, a significant reduction of SOCS1 has been measured in parallel with the synthesis of proinflammatory cytokines in MS (<xref ref-type="bibr" rid="B40">Toghi et al., 2017</xref>). In agreement with <xref ref-type="bibr" rid="B40">Toghi et al. (2017)</xref>, a substantial number of DNAme groups to SOCS1 might result in an acute inflammatory response, as has been reported in the context of MS (<xref ref-type="bibr" rid="B24">Liggett et al., 2010</xref>; <xref ref-type="bibr" rid="B37">Sokratous et al., 2018</xref>).</p>
</sec>
<sec id="s1_4">
<title>Deoxyribonucleic Acid Damage</title>
<p>The endoplasmic reticulum (ER), along with the plasma membrane (PM) junctions, is essential for Ca<sup>2+</sup> homeostasis. ER Ca<sup>2+</sup> depletion potentiates the inflammatory response, ER stress and, lastly, DNA damage (<xref ref-type="bibr" rid="B44">Woo et al., 2016</xref>). Upon activation of T-cell receptors (TCRs), protein junctions containing membrane occupation and recognition nexus (MORN) motifs stimulate a Ca<sup>2+</sup> influx in T cells. Deficiency of protein junctions containing MORN motifs aggravates the store-operated Ca<sup>2+</sup> entry in T cells and causes DNA damage (<xref ref-type="bibr" rid="B44">Woo et al., 2016</xref>). An elevated number of DNAme groups to MORN repeat containing 1 (MORN1) has been reported in both CD4+ and CD8+ T cells collected from MS patients (<xref ref-type="bibr" rid="B12">Graves et al., 2014</xref>; <xref ref-type="bibr" rid="B27">Maltby et al., 2015</xref>) and might affect T cell viability (<xref ref-type="bibr" rid="B44">Woo et al., 2016</xref>). On the other hand, pleckstrin and Sec7 domain-containing 3 (PSD3) are predominantly expressed in the CNS (<xref ref-type="bibr" rid="B36">Schraut et al., 2014</xref>), as well as in T cells, macrophages, and neutrophils (<xref ref-type="bibr" rid="B32">Okada et al., 2012</xref>). The Sec7 domain of PSD3 protein is a guanine nucleotide exchange factor for small GTPases that contributes to neurite formation, spine density, trafficking of synaptic vesicles, and receptor internalization (<xref ref-type="bibr" rid="B32">Okada et al., 2012</xref>). High levels of PSD3 activate Fas-induced apoptosis, while its depletion disrupts cell shape and polarity (<xref ref-type="bibr" rid="B32">Okada et al., 2012</xref>). In MS, a hypomethylation of PSD3 has been reported in both CD8+ T cells (<xref ref-type="bibr" rid="B4">Bos et al., 2015</xref>) and demyelinated hippocampi (<xref ref-type="bibr" rid="B5">Chomyk et al., 2017</xref>). This might suggest that immune homeostasis is unbalanced under these conditions (<xref ref-type="bibr" rid="B32">Okada et al., 2012</xref>).</p>
<p><italic>De novo</italic> telomere addition of long interspersed nuclear elements (LINE-1) into genomic DNA causes genetic defects, alters the regulatory mechanisms and the structural properties of the genome at their insertion place and might lead to genomic remodeling (<xref ref-type="bibr" rid="B8">Furano, 2000</xref>). Changes in LINE-1 methylation status have been described in MS patients. Indeed, LINE-1 CpG sites were more frequently methylated in MS patients than in controls (<xref ref-type="bibr" rid="B35">Pinto-Medel et al., 2017</xref>; <xref ref-type="bibr" rid="B6">Dunaeva et al., 2018</xref>). A hypermethylated DNA pattern for LINE-1 in MS might be related to chromosomal abnormalities and DNA damage (<xref ref-type="bibr" rid="B35">Pinto-Medel et al., 2017</xref>).</p>
</sec>
<sec id="s1_5">
<title>The Central Nervous System</title>
<p>Observations of human MS plaques have revealed an increase of protein tyrosine phosphatases (PTPs) during ongoing remyelination (<xref ref-type="bibr" rid="B15">Hendriks et al., 2013</xref>). In NAWM derived from MS patients, the addition of DNAme to PTPRN2 (<xref ref-type="bibr" rid="B17">Huynh et al., 2014</xref>), a member of the PTP family, indicates that the CNS integrity remains unaltered. An upregulation of TGFBI is involved in CNS repair after brain injury through the inhibition of the inflammatory response, mediated by activated microglia. Therefore, TGFBI acts as a suppressor of microgliosis (<xref ref-type="bibr" rid="B19">Kim and Lee, 2011</xref>). Consequently, lower DNAme levels to TGFBI in the demyelinated hippocampus of MS patients might occur in order to counteract the deleterious effect associated with the activation of microglia (<xref ref-type="bibr" rid="B19">Kim and Lee, 2011</xref>). Kinesins (KIFs), a family of motor proteins mainly expressed in neurons, immune cells, and oligodendrocytes, are involved in the trafficking of vesicles, organelles, and proteins through the cytoskeleton (<xref ref-type="bibr" rid="B16">Hirokawa and Takemura, 2013</xref>). An overexpression of KIF improves axonal transport, while its downregulation leads to neurodegeneration and CNS atrophy (<xref ref-type="bibr" rid="B26">Lo Giudice et al., 2006</xref>). Dysregulation of certain KIFs has been postulated to aggravate MS disease (<xref ref-type="bibr" rid="B14">Hares et al., 2014</xref>). Lower methylated levels for KIF family member 25 (KIF25) have been measured in the hippocampi (<xref ref-type="bibr" rid="B5">Chomyk et al., 2017</xref>) and CD4+ T cells (<xref ref-type="bibr" rid="B12">Graves et al., 2014</xref>) of MS patients. Thus, it is plausible that lower DNAme levels could increase the production of KIF motor proteins to compensate the increased CNS molecule transport demand in MS patients. Cell adhesion molecules (CAMs) participate in axon guidance, synaptogenesis, and neuronal regeneration (<xref ref-type="bibr" rid="B13">Hansen and Walmod, 2013</xref>). Immunoglobulin superfamily member 9B (IGSF9B) is a member of the CAM family highly expressed in GABAergic interneurons, macrophages/microglia, and astrocytes (<xref ref-type="bibr" rid="B10">Gil-Varea et al., 2018</xref>). IGSF9B is also constitutively expressed in circulating monocytes (<xref ref-type="bibr" rid="B41">Tserel et al., 2014</xref>); however, its biological function in this cell type remains unclear and thus requires further investigation. Elevated expression of IGSF9B favors the maintenance of inhibitory synapses (<xref ref-type="bibr" rid="B10">Gil-Varea et al., 2018</xref>), while low levels result in a selective loss of GABAergic interneurons (<xref ref-type="bibr" rid="B30">Mishra et al., 2014</xref>). A prominent loss of GABAergic circuits has been described in MS (<xref ref-type="bibr" rid="B10">Gil-Varea et al., 2018</xref>). The findings reported by <xref ref-type="bibr" rid="B5">Chomyk et al. (2017)</xref> and <xref ref-type="bibr" rid="B21">Kulakova et al. (2016)</xref> suggest that a substantial number of DNAme to IGSF9B could be accompanied by lower transcription rates as well as a selective loss of GABAergic interneurons (<xref ref-type="bibr" rid="B10">Gil-Varea et al., 2018</xref>). In MS, HLA class I histocompatibility antigen, alpha chain F (HLA-F) cooperates with the antigen-processing peptide-loading complex, regulating the immune response <italic>via</italic> NK receptors (<xref ref-type="bibr" rid="B2">Alcina et al., 2012</xref>). An overexpression of HLA-F protects neurons from astrocyte-mediated neurotoxicity (<xref ref-type="bibr" rid="B38">Song et al., 2016</xref>). Thus, it can be hypothesized that a lower number of methyl groups to HLA-F might confer neuroprotection. In this regard, <xref ref-type="bibr" rid="B17">Huynh et al. (2014)</xref> found a hypomethylation of HLA-F promoter in NAWM collected from MS patients compared to their controls. It is noteworthy that RUNX3, a transcription factor importantly involved in DC and T and NK cell differentiation, is upregulated in active and chronic MS lesions (<xref ref-type="bibr" rid="B37">Sokratous et al., 2018</xref>). Similarly, <xref ref-type="bibr" rid="B17">Huynh et al. (2014)</xref> reported a hypomethylated DNA pattern for RUNX3 in NAWM collected from MS patients. This indicates that RUNX3 DNAme status could be used as an inflammatory biomarker even when inflammation is apparently not present in the CNS (<xref ref-type="bibr" rid="B17">Huynh et al., 2014</xref>). When retinoic acid (RA) interacts with retinoic acid receptor alpha (RARA), several transcriptional changes affecting the immune system and CNS repair can take place. Indeed, the inflammatory activity observed in MS patients is attenuated upon stimulation of RARA (<xref ref-type="bibr" rid="B20">Kim et al., 2017</xref>). In line with these findings, <xref ref-type="bibr" rid="B17">Huynh et al. (2014)</xref> reported a hypomethylated DNAme pattern for RARA in MS NAWM, which suggests no inflammatory activity (<xref ref-type="bibr" rid="B17">Huynh et al., 2014</xref>). Additionally, <xref ref-type="bibr" rid="B28">Marabita et al. (2017)</xref> found a smaller number of DNAme groups for RARA in tobacco smokers with MS compared to non-smokers diagnosed with MS, which is apparently related to tobacco consumption (<xref ref-type="bibr" rid="B39">Su et al., 2016</xref>). Cadherins are widespread calcium-dependent cell adhesion proteins involved in cell-cell adhesion, mobility, and proliferation of epithelial cells. In particular, cadherin 1 (CDH1) participates in many aspects of synapse formation and function (<xref ref-type="bibr" rid="B3">Almeida and Lyons, 2014</xref>). Recently, <xref ref-type="bibr" rid="B18">James et al. (2018)</xref> identified a large percentage of single nucleotide polymorphisms (SNPs) that may confer risk of MS. Among them, rs1886700 is statistically associated with lower expression of CDH1. Therefore, an increase of DNAme to CDH1 (<xref ref-type="bibr" rid="B24">Liggett et al., 2010</xref>; <xref ref-type="bibr" rid="B17">Huynh et al., 2014</xref>) probably leads to lower mRNA transcription rates and a worse disease course in MS (<xref ref-type="bibr" rid="B18">James et al., 2018</xref>).</p>
</sec>
</sec>
<sec id="s2" sec-type="conclusions">
<title>Conclusions and Perspectives</title>
<p>Multiple sclerosis is a chronic inflammatory CNS disease originating from a complex interaction between genes and the environment. As far as we know, genetics accounts for almost 30% of MS prevalence worldwide, while the remaining percentage corresponds to epigenetic modifications due to exposure to distinct environmental factors (<xref ref-type="bibr" rid="B43">Weber et al., 2007</xref>). This review summarized the common differentially methylated genes expressed in distinct cell types and tissues derived from MS patients in order to elucidate their role in the pathophysiology of the disease. We conclude that changes in the methylation status of certain genes cause chromosomal abnormalities, DNA damage, and the generation of pathogenic immune cells resulting in inadequate innate and adaptive immune response. Furthermore, we assume that aberrant epigenetic profile in the context of disease potentiates microgliosis, alterations in synapse formation and function, and a selective loss of GABAergic interneurons which in turn favors neurodegeneration. A deeper understanding of the underlying physiological mechanisms mediated by DNAme will contribute to the development of new strategies in MS prognosis and therapy.</p>
</sec>
<sec id="s3">
<title>Author Contributions</title>
<p>NC and JT-R researched the literature and drafted the manuscript. JT-R critically reviewed and edited the work. Both authors read and approved the final manuscript.</p>
</sec>
<sec id="s4" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This review was funded by the Deutsche Forschungsgemeinschaft to Dr. Jordi Tomas Roig (ref. TO 977/1-1) and the University of Girona to Mrs Naiara Celarain Sanz (ref. IFUdG2017).</p>
</sec>
<sec id="s5">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<sec id="s6">
<title>Abbreviations</title>
<p>MS, multiple sclerosis; CNS, central nervous system; APC, antigen presenting cells; Th, T helper cells; BBB, blood brain barrier; miRNA, microRNA; Me, methylation; Ub, ubiquitination; Ac, acetylation; P, phosphorylation; DNAme, DNA methylation; PBMCs, peripheral blood mononuclear cells; <italic>AHR</italic>, aryl hydrocarbon receptor; <italic>AHRR</italic>, aryl-hydrocarbon receptor repressor; <italic>MHC</italic>, major histocompatibility complex; <italic>MICA</italic>, MHC class I chain-related gene A; <italic>MICB</italic>, MHC class I chain-related gene B; NK, natural killer; <italic>RUNX3</italic>, runt related transcription factor 3; DC, dendritic cells; <italic>CDKN2A</italic>, cyclin dependent kinase inhibitor 2A; <italic>GNAS</italic>, guanine nucleotide binding protein alpha stimulating; IFN, type I interferon; <italic>USP35</italic>, ubiquitin specific peptidase 35; <italic>ATP11A</italic>, ATPase phospholipid transporting 11A; <italic>TLR4</italic>, toll-like receptor 4; pTh17, pathogenic Th17 cells; <italic>RASA3</italic>, RAS p21 protein activator 3; NAWM, normal appearing white matter; <italic>HOXC4</italic>, homeobox C4; <italic>PTPRN2</italic>, protein tyrosine phosphatase receptor type N2; <italic>SMAD3</italic>, SMAD family member 3; <italic>TGFBI</italic>, transforming growth factor beta induced; <italic>SOCS1</italic>, suppressor of cytokine signaling 1; ER, endoplasmic reticulum; PM, plasma membrane; TCRs, T-cell receptors; <italic>MORN1</italic>, MORN repeat containing 1; <italic>PSD3</italic>, pleckstrin and sec7 domain containing 3; <italic>LINE-1</italic>, long interspersed nuclear element; PTPs, protein tyrosine phosphatases; <italic>KIF25</italic>, kinesin family member 25; CAM, cell adhesion molecules; <italic>IGSF9B</italic>, immunoglobulin superfamily member 9B; <italic>HLA-F</italic>, HLA class I histocompatibility antigen alpha chain F; RA, retinoic acid; <italic>RARA</italic>, retinoic acid receptor alpha; <italic>CDH1</italic>, cadherin 1.</p>
</sec>
  
<sec sec-type="supplementary-material" id="s7">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fgene.2019.01138/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fgene.2019.01138/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Table_1.docx" id="SM1" mimetype="application/docx"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abediankenari</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Yousefzadeh</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Majidi</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Ghasemi</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Nasehi</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Ghaffari</surname> <given-names>J.</given-names>
</name>
<etal/>
</person-group>. (<year>2011</year>). <article-title>MICB gene expression on peripheral blood mononuclear cells and susceptibility to multiple sclerosis in North of Iran</article-title>. <source>Iran J. Allergy Asthma Immunol.</source> <volume>10</volume> (<issue>4</issue>), <fpage>261</fpage>&#x2013;<lpage>265</lpage>. doi: 0<pub-id pub-id-type="doi">10.04/ijaai.261265</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alcina</surname> <given-names>A.</given-names>
</name>
<name>
<surname>de Abad-Grau</surname> <given-names>M. M.</given-names>
</name>
<name>
<surname>Fedetz</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Izquierdo</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Lucas</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Fern&#xe1;ndez</surname> <given-names>&#xd3;</given-names>
</name>
<etal/>
</person-group>. (<year>2012</year>). <article-title>Multiple sclerosis risk variant HLA-DRB1*1501 associates with high expression of DRB1 gene in different human populations</article-title>. <source>PloS One</source> <volume>7</volume> (<issue>1</issue>), <elocation-id>e29819</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0029819</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Almeida</surname> <given-names>R. G.</given-names>
</name>
<name>
<surname>Lyons</surname> <given-names>D. A.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>On the resemblance of synapse formation and CNS myelination</article-title>. <source>Neuroscience</source> <volume>276</volume>, <fpage>98</fpage>&#x2013;<lpage>108</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuroscience.2013.08.062</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bos</surname> <given-names>S. D.</given-names>
</name>
<name>
<surname>Page</surname> <given-names>C. M.</given-names>
</name>
<name>
<surname>Andreassen</surname> <given-names>B. K.</given-names>
</name>
<name>
<surname>Elboudwarej</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Gustavsen</surname> <given-names>M. W.</given-names>
</name>
<name>
<surname>Briggs</surname> <given-names>F.</given-names>
</name>
<etal/>
</person-group>. (<year>2015</year>). <article-title>Genome-wide DNA methylation profiles indicate CD8+ T cell hypermethylation in multiple sclerosis</article-title>. <source>PloS One</source> <volume>10</volume> (<issue>3</issue>), <elocation-id>e0117403</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0117403</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chomyk</surname> <given-names>A. M.</given-names>
</name>
<name>
<surname>Volsko</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Tripathi</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Deckard</surname> <given-names>S. A.</given-names>
</name>
<name>
<surname>Trapp</surname> <given-names>B. D.</given-names>
</name>
<name>
<surname>Fox</surname> <given-names>R. J.</given-names>
</name>
<etal/>
</person-group>. (<year>2017</year>). <article-title>DNA methylation in demyelinated multiple sclerosis hippocampus</article-title>. <source>Sci. Rep.</source> <volume>7</volume>, <fpage>8696</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-017-08623-5</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dunaeva</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Derksen</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Pruijn</surname> <given-names>G. J. M.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>LINE-1 hypermethylation in serum cell-free DNA of relapsing remitting multiple sclerosis patients</article-title>. <source>Mol. Neurobiol.</source> <volume>55</volume> (<issue>6</issue>), <fpage>4681</fpage>&#x2013;<lpage>4688</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12035-017-0679-z</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandez-Morera</surname> <given-names>J. L.</given-names>
</name>
<name>
<surname>Rodriguez-Rodero</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Tunon</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Martinez-Borra</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Vidal-Castineira</surname> <given-names>J. R.</given-names>
</name>
<name>
<surname>Lopez-Vazquez</surname> <given-names>A.</given-names>
</name>
<etal/>
</person-group>. (<year>2008</year>). <article-title>Genetic influence of the nonclassical major histocompatibility complex class I molecule MICB in multiple sclerosis susceptibility</article-title>. <source>Tissue Antigens</source> <volume>72</volume> (<issue>1</issue>), <fpage>54</fpage>&#x2013;<lpage>59</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1399-0039.2008.01066.x</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Furano</surname> <given-names>A. V.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>The biological properties and evolutionary dynamics of mammalian LINE-1 retrotransposons</article-title>. <source>Prog. Nucleic Acid Res. Mol. Biol. [Internet]</source> <volume>64</volume>, <fpage>255</fpage>&#x2013;<lpage>294</lpage>.</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghasemi</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Razavi</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Nikzad</surname> <given-names>E.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy</article-title>. <source>Cell J.</source> <volume>19</volume>, <fpage>1</fpage>&#x2013;<lpage>10</lpage>. doi: <pub-id pub-id-type="doi">10.22074/cellj.2016.4867</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gil-Varea</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Urcelay</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Vilari&#xf1;o-G&#xfc;ell</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Costa</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Midaglia</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Matesanz</surname> <given-names>F.</given-names>
</name>
<etal/>
</person-group>. (<year>2018</year>). <article-title>Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course</article-title>. <source>J. Neuroinflamm.</source> <volume>15</volume>(<issue>1</issue>), <fpage>265</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12974-018-1307-1</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Graca</surname> <given-names>L.</given-names>
</name>
</person-group> (<year>2007</year>). <source>The Immune Synapse as a Novel Target for Therapy.</source> <publisher-loc>Berlin, Germany</publisher-loc>: <publisher-name>Springer Science &amp; Business Media</publisher-name>;, <fpage>192</fpage>.</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Graves</surname> <given-names>M. C.</given-names>
</name>
<name>
<surname>Benton</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Lea</surname> <given-names>R. A.</given-names>
</name>
<name>
<surname>Boyle</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Tajouri</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Macartney-Coxson</surname> <given-names>D.</given-names>
</name>
<etal/>
</person-group>. (<year>2014</year>). <article-title>Methylation differences at the HLA-DRB1 locus in CD4+ T-Cells are associated with multiple sclerosis</article-title>. <source>Multiple Sclerosis (Houndmills Basingstoke England)</source> <volume>20</volume>, <fpage>1033</fpage>&#x2013;<lpage>1041</lpage>. doi: <pub-id pub-id-type="doi">10.1177/1352458513516529</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hansen</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Walmod</surname> <given-names>P. S.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>IGSF9 family proteins</article-title>. <source>Neurochem. Res.</source> <volume>38</volume>, <fpage>1236</fpage>&#x2013;<lpage>1251</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11064-013-0999-y</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hares</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Kemp</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Rice</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Gray</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Scolding</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Wilkins</surname> <given-names>A.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Reduced axonal motor protein expression in non-Lesional grey matter in multiple sclerosis</article-title>. <source>Mult. Scler. J.</source> <volume>20</volume> (<issue>7</issue>), <fpage>812</fpage>&#x2013;<lpage>821</lpage>. doi: <pub-id pub-id-type="doi">10.1177/1352458513508836</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hendriks</surname> <given-names>W. J. A. J.</given-names>
</name>
<name>
<surname>Elson</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Harroch</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Pulido</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Stoker</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Den Hertog</surname> <given-names>J.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Protein tyrosine phosphatases in health and disease</article-title>. <source>FEBS J.</source> <volume>280</volume>p, <fpage>708</fpage>&#x2013;<lpage>730</lpage>. doi: <pub-id pub-id-type="doi">10.1111/febs.12000</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Hirokawa</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Takemura</surname> <given-names>R.</given-names>
</name>
</person-group>, (<year>2013</year>). &#x201c;<article-title>Kinesin Superfamily Proteins</article-title>,&#x201d; in <source>Encyclopedia of Biological Chemistry</source>: (<publisher-loc>Waltham</publisher-loc>: <publisher-name>Academic Press</publisher-name>) <edition>Second Edition</edition>, <fpage>679</fpage>&#x2013;<lpage>687</lpage>.</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huynh</surname> <given-names>J. L.</given-names>
</name>
<name>
<surname>Garg</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Thin</surname> <given-names>T. H.</given-names>
</name>
<name>
<surname>Yoo</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Dutta</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Trapp</surname> <given-names>B. D.</given-names>
</name>
<etal/>
</person-group>. (<year>2014</year>). <article-title>Epigenome-wide differences in pathology-free regions of multiple sclerosis-affected brains</article-title>. <source>Nat. Neurosci.</source> <volume>17</volume>, <fpage>121</fpage>&#x2013;<lpage>130</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nn.3588</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>James</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Lind&#xe9;n</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Morikawa</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Fernandes</surname> <given-names>S. J.</given-names>
</name>
<name>
<surname>Ruhrmann</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Huss</surname> <given-names>M.</given-names>
</name>
<etal/>
</person-group>. (<year>2018</year>). <article-title>Impact of genetic risk loci for multiple sclerosis on expression of proximal genes in patients</article-title>. <source>Hum. Mol. Genet.</source> <volume>27</volume> (<issue>5</issue>), <fpage>912</fpage>&#x2013;<lpage>928</lpage>. doi: <pub-id pub-id-type="doi">10.1093/hmg/ddy001</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>E. H.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Molecular mechanisms of microglial deactivation by TGF-&#x3b2;-inducible protein &#x3b2;ig-h3</article-title>. <source>Integr. Biosci.</source> <volume>9</volume> (<issue>2</issue>), <fpage>101</fpage>&#x2013;<lpage>105</lpage>. doi: <pub-id pub-id-type="doi">10.1080/17386357.2005.9647258</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname> <given-names>S. Y.</given-names>
</name>
<name>
<surname>Kelland</surname> <given-names>E. E.</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>J. H.</given-names>
</name>
<name>
<surname>Lund</surname> <given-names>B. T.</given-names>
</name>
<name>
<surname>Chang</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>K.</given-names>
</name>
<etal/>
</person-group>. (<year>2017</year>). <article-title>The influence of retinoic acid on the human oligodendrocyte precursor cells by RNA-sequencing</article-title>. <source>Biochem. Biophys. Rep.</source> <volume>9</volume>, <fpage>166</fpage>&#x2013;<lpage>172</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbrep.2016.12.004</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kulakova</surname> <given-names>O. G.</given-names>
</name>
<name>
<surname>Kabilov</surname> <given-names>M. R.</given-names>
</name>
<name>
<surname>Danilova</surname> <given-names>L. V.</given-names>
</name>
<name>
<surname>Popova</surname> <given-names>E. V.</given-names>
</name>
<name>
<surname>Baturina</surname> <given-names>O. A.</given-names>
</name>
<name>
<surname>Tsareva</surname> <given-names>E. Y.</given-names>
</name>
<etal/>
</person-group>. (<year>2016</year>). <article-title>Whole-Genome DNA methylation analysis of peripheral blood mononuclear cells in multiple sclerosis patients with different disease courses</article-title>. <source>Acta Naturae</source> <volume>8</volume>, <fpage>103</fpage>&#x2013;<lpage>110</lpage>.</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>T. H.</given-names>
</name>
<name>
<surname>Murray</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Choi</surname> <given-names>S. S.</given-names>
</name>
<name>
<surname>Broide</surname> <given-names>D. H.</given-names>
</name>
<etal/>
</person-group>. (<year>2015</year>). <article-title>Cyclic AMP concentrations in dendritic cells induce and regulate Th2 immunity and allergic asthma</article-title>. <source>Proc. Natl. Acad. Sci.</source> <volume>112</volume> (<issue>5</issue>), <fpage>1529</fpage>&#x2013;<lpage>1534</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1417972112</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname> <given-names>S. A.</given-names>
</name>
<name>
<surname>Mefford</surname> <given-names>J. A.</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Witte</surname> <given-names>J. S.</given-names>
</name>
<name>
<surname>Martin</surname> <given-names>J. N.</given-names>
</name>
<name>
<surname>Haas</surname> <given-names>D. W.</given-names>
</name>
<etal/>
</person-group>. (<year>2016</year>). <article-title>Host genetic predictors of the kynurenine pathway of tryptophan catabolism among treated HIV-infected Ugandans</article-title>. <source>AIDS</source> <volume>30</volume> (<issue>11</issue>), <fpage>1807</fpage>&#x2013;<lpage>1815</lpage>. doi: <pub-id pub-id-type="doi">10.1097/QAD.0000000000001124</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liggett</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Melnikov</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Tilwalli</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Yi</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Replogle</surname> <given-names>C.</given-names>
</name>
<etal/>
</person-group>. (<year>2010</year>). <article-title>Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis</article-title>. <source>J. Neuro. Sci.</source> <volume>290</volume>, <fpage>16</fpage>&#x2013;<lpage>21</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jns.2009.12.018</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Qin</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Xie</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Xiao-Feng Qin</surname> <given-names>F.</given-names>
</name>
<etal/>
</person-group>. (<year>2018</year>). <article-title>Broad and diverse mechanisms used by deubiquitinase family members in regulating the type i interferon signaling pathway during antiviral responses</article-title>. <source>Sci. Adv.</source> <volume>4</volume>(<issue>5</issue>), <fpage>eaar2824</fpage>. doi: <pub-id pub-id-type="doi">10.1126/sciadv.aar2824</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lo Giudice</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Neri</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Falco</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Sturnio</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Calzolari</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Di Benedetto</surname> <given-names>D.</given-names>
</name>
<etal/>
</person-group>. (<year>2006</year>). <article-title>A missense mutation in the coiled-coil domain of the KIF5A gene and late-onset hereditary spastic paraplegia</article-title>. <source>Arch. Neurol.</source> <volume>63</volume> (<issue>2</issue>), <fpage>284</fpage>&#x2013;<lpage>287</lpage>.</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maltby</surname> <given-names>V. E.</given-names>
</name>
<name>
<surname>Graves</surname> <given-names>M. C.</given-names>
</name>
<name>
<surname>Lea</surname> <given-names>R. A.</given-names>
</name>
<name>
<surname>Benton</surname> <given-names>M. C.</given-names>
</name>
<name>
<surname>Sanders</surname> <given-names>K. A.</given-names>
</name>
<name>
<surname>Tajouri</surname> <given-names>L.</given-names>
</name>
<etal/>
</person-group>. (<year>2015</year>). <article-title>Genome-wide DNA methylation profiling of CD8+ T cells shows a distinct epigenetic signature to CD4+ T cells in multiple sclerosis patients</article-title>. <source>Clin. Epigenet.</source> <volume>9</volume>, <elocation-id>71</elocation-id>. doi: <pub-id pub-id-type="doi">10.1186/s13148-017-0371-1</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marabita</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Almgren</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Sj&#xf6;holm</surname> <given-names>L. K.</given-names>
</name>
<name>
<surname>Kular</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>James</surname> <given-names>T.</given-names>
</name>
<etal/>
</person-group>. (<year>2017</year>). <article-title>Smoking induces DNA methylation changes in Multiple Sclerosis patients with exposure-response relationship</article-title>. <source>Sci. Rep.</source> <volume>7</volume> (<issue>1</issue>), <fpage>14589</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-017-14788-w</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marchetti</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Ziliotto</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Meneghetti</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Baroni</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Lunghi</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Menegatti</surname> <given-names>E.</given-names>
</name>
<etal/>
</person-group>. (<year>2018</year>). <article-title>Changes in expression profiles of internal jugular vein wall and plasma protein levels in multiple sclerosis</article-title>. <source>Mol. Med.</source> <volume>24</volume>(<issue>1</issue>), <fpage>42</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s10020-018-0043-4</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mishra</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Traut</surname> <given-names>M. H.</given-names>
</name>
<name>
<surname>Becker</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Klopstock</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Stein</surname> <given-names>V.</given-names>
</name>
<name>
<surname>Klein</surname> <given-names>R.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>genetic evidence for the adhesion protein IgSF9/Dasm1 to regulate inhibitory synapse development independent of its intracellular domain</article-title>. <source>J. Neurosci.</source> <volume>34</volume> (<issue>12</issue>), <fpage>4187</fpage>&#x2013;<lpage>4199</lpage>. doi: <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3671-13.2014</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neavin</surname> <given-names>D. R.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Ray</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Weinshilboum</surname> <given-names>R. M.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>The role of the aryl hydrocarbon receptor (AHR) in immune and inflammatory diseases</article-title>. <source>Int. J. Mol. Sci.</source> <volume>19</volume>(<issue>12</issue>). pii: <fpage>E3851</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms19123851</pub-id>.
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okada</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Suzuki</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Takaharu</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Noda</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Kamiyama</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Maeda</surname> <given-names>T.</given-names>
</name>
<etal/>
</person-group>. (<year>2012</year>). <article-title>Aberrant methylation of the Pleckstrin and Sec7 domain-containing gene is implicated in ulcerative colitis-associated carcinogenesis through its inhibitory effect on apoptosis</article-title>. <source>Int. J. Oncol.</source> <volume>40</volume> (<issue>3</issue>), <fpage>686</fpage>&#x2013;<lpage>694</lpage>. doi: <pub-id pub-id-type="doi">10.3892/ijo.2011.1231</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname> <given-names>S. R.</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>P. H.</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>K. S.</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>S. H.</given-names>
</name>
<name>
<surname>Seo</surname> <given-names>G. Y.</given-names>
</name>
<name>
<surname>Yoo</surname> <given-names>Y. C.</given-names>
</name>
<etal/>
</person-group>. (<year>2013</year>). <article-title>APRIL stimulates NF-&#x3ba;B-mediated HoxC4 induction for AID expression in mouse B cells</article-title>. <source>Cytokine</source> <volume>61</volume> (<issue>2</issue>), <fpage>608</fpage>&#x2013;<lpage>613</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cyto.2012.10.018</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parnell</surname> <given-names>G. P.</given-names>
</name>
<name>
<surname>Gatt</surname> <given-names>P. N.</given-names>
</name>
<name>
<surname>Krupa</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Nickles</surname> <given-names>D.</given-names>
</name>
<name>
<surname>McKay</surname> <given-names>F. C.</given-names>
</name>
<name>
<surname>Schibeci</surname> <given-names>S. D.</given-names>
</name>
<etal/>
</person-group>. (<year>2014</year>). <article-title>The autoimmune disease-associated transcription factors EOMES and TBX21 are dysregulated in multiple sclerosis and define a molecular subtype of disease</article-title>. <source>Clin. Immunol.</source> <volume>151</volume> (<issue>1</issue>), <fpage>16</fpage>&#x2013;<lpage>24</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.clim.2014.01.003</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinto-Medel</surname> <given-names>M. J.</given-names>
</name>
<name>
<surname>Oliver-Martos</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Urbaneja-Romero</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Hurtado-Guerrero</surname> <given-names>I.</given-names>
</name>
<name>
<surname>Ortega-Pinazo</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Serrano-Castro</surname> <given-names>P.</given-names>
</name>
<etal/>
</person-group>. (<year>2017</year>). <article-title>Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatment</article-title>. <source>Sci. Rep.</source> <volume>7</volume> (<issue>1</issue>), <fpage>8727</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-017-09301-2</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schraut</surname> <given-names>K. G.</given-names>
</name>
<name>
<surname>Jakob</surname> <given-names>S. B.</given-names>
</name>
<name>
<surname>Weidner</surname> <given-names>M. T.</given-names>
</name>
<name>
<surname>Schmitt</surname> <given-names>A. G.</given-names>
</name>
<name>
<surname>Scholz</surname> <given-names>C. J.</given-names>
</name>
<name>
<surname>Strekalova</surname> <given-names>T.</given-names>
</name>
<etal/>
</person-group>. (<year>2014</year>). <article-title>Prenatal stress-induced programming of genome-wide promoter DNA methylation in 5-HTT-deficient mice</article-title>. <source>Transl. Psychiatry</source> <volume>4</volume>, <fpage>e473</fpage>. doi: <pub-id pub-id-type="doi">10.1038/tp.2014.107</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sokratous</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Dardiotis</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Bellou</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Tsouris</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Michalopoulou</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Dardioti</surname> <given-names>M.</given-names>
</name>
<etal/>
</person-group>. (<year>2018</year>). <article-title>CpG island methylation patterns in relapsing-remitting multiple sclerosis</article-title>. <source>J. Mol. Neurosci. J. Mol. Neurosci.</source> <volume>64</volume>, <fpage>478</fpage>&#x2013;<lpage>484</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12031-018-1046-x</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname> <given-names>S. W.</given-names>
</name>
<name>
<surname>Miranda</surname> <given-names>C. J.</given-names>
</name>
<name>
<surname>Braun</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Meyer</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Frakes</surname> <given-names>A. E.</given-names>
</name>
<name>
<surname>Ferraiuolo</surname> <given-names>L.</given-names>
</name>
<etal/>
</person-group>. (<year>2016</year>). <article-title>Major histocompatibility complex class I molecules protect motor neurons from astrocyte-induced toxicity in amyotrophic lateral sclerosis</article-title>. <source>Nat. Med.</source> <volume>22</volume> (<issue>4</issue>), <fpage>397</fpage>&#x2013;<lpage>403</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nm.4052</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Su</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Campbell</surname> <given-names>M. R.</given-names>
</name>
<name>
<surname>Porter</surname> <given-names>D. K.</given-names>
</name>
<name>
<surname>Pittman</surname> <given-names>G. S.</given-names>
</name>
<name>
<surname>Bennett</surname> <given-names>B. D.</given-names>
</name>
<etal/>
</person-group>. (<year>2016</year>). <article-title>Distinct epigenetic effects of tobacco smoking in whole blood and among leukocyte subtypes</article-title>. <source>PloS One</source> <volume>11</volume> (<issue>12</issue>), <elocation-id>e0166486</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0166486</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Toghi</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Taheri</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Arsang-Jang</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Ohadi</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Mirfakhraie</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Mazdeh</surname> <given-names>M.</given-names>
</name>
<etal/>
</person-group>. (<year>2017</year>). <article-title>SOCS gene family expression profile in the blood of multiple sclerosis patients</article-title>. <source>J. Neurol. Sci.</source> <volume>375</volume>, <fpage>481</fpage>&#x2013;<lpage>485</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jns.2017.02.015</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tserel</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Limbach</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Saare</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Kisand</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Metspalu</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Milani</surname> <given-names>L.</given-names>
</name>
<etal/>
</person-group>. (<year>2014</year>). <article-title>CpG sites associated with NRP1, NRXN2 and miR-29b-2 are hypomethylated in monocytes during ageing</article-title>. <source>Immun. Ageing</source> <volume>11</volume> (<issue>1</issue>), <elocation-id>1</elocation-id>. doi: <pub-id pub-id-type="doi">10.1186/1742-4933-11-1</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Mark</surname> <given-names>V. A.</given-names>
</name>
<name>
<surname>Ghiboub</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Marsman</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>J.</given-names>
</name>
<name>
<surname>van Dijk</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Hiralall</surname> <given-names>J. K.</given-names>
</name>
<etal/>
</person-group>. (<year>2017</year>). <article-title>Phospholipid flippases attenuate LPS-induced TLR4 signaling by mediating endocytic retrieval of Toll-like receptor 4</article-title>. <source>Cell Mol. Life Sci.</source> <volume>74</volume> (<issue>4</issue>), <fpage>715</fpage>&#x2013;<lpage>730</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00018-016-2360-5</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weber</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Hellmann</surname> <given-names>I.</given-names>
</name>
<name>
<surname>Stadler</surname> <given-names>M. B.</given-names>
</name>
<name>
<surname>Ramos</surname> <given-names>L.</given-names>
</name>
<name>
<surname>P&#xe4;&#xe4;bo</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Rebhan</surname> <given-names>M.</given-names>
</name>
<etal/>
</person-group>. (<year>2007</year>). <article-title>Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome</article-title>. <source>Nat. Genet.</source> <volume>39</volume>, <fpage>457</fpage>&#x2013;<lpage>466</lpage>. doi: <pub-id pub-id-type="doi">10.1038/ng1990</pub-id>
</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Woo</surname> <given-names>J. S.</given-names>
</name>
<name>
<surname>Srikanth</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Nishi</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Ping</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Takeshima</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Gwack</surname> <given-names>Y.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Junctophilin-4, a component of the endoplasmic reticulum&#x2013;plasma membrane junctions, regulates Ca<sup>2+</sup> dynamics in T cells</article-title>. <source>Proc. Natl. Acad. Sci. [Internet]</source> <volume>113</volume> (<issue>10</issue>), <fpage>2762</fpage>&#x2013;<lpage>2767</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1524229113</pub-id>
</citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Xie</surname> <given-names>L.</given-names>
</name>
<etal/>
</person-group>. (<year>2018</year>). <article-title>RAS P21 protein activator 3 (RASA3) specifically promotes pathogenic T Helper 17 cell generation by repressing T-Helper-2-cell-biased programs</article-title>. <source>Immunity</source> <volume>49</volume> (<issue>5</issue>), <fpage>886</fpage>&#x2013;<lpage>898</lpage>.<fpage>e5</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2018.09.004</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>